a1 Department of Pediatrics, Hackensack University Medical Center, Hackensack, United States
a2 Department of Pediatrics, University of Medicine and Dentistry of New Jersey, Newark, United States
a3 Research Department, Hackensack University Medical Center, Hackensack, New Jersey, United States
Introduction Propranolol was recently discovered to be an effective treatment for infantile haemangiomas, and varying doses and monitoring regimens have been proposed. Adverse events, although uncommon, have been reported.
Materials and methods This was a retrospective chart review of infants with haemangiomas who were started on propranolol at a dose of 3 milligrams per kilogram per day on an outpatient basis. After a baseline cardiac evaluation including an electrocardiogram and an echocardiogram, treatment was initiated during 6 hours of observation.
Results A total of 15 patients were identified; however, only 13 returned for at least one follow-up visit. This cohort was followed up for a median of 2.8 months with a range from 0.2 to 10.0. No hypotension, hypoglycaemia, bronchospasm, or clinically significant bradycardia occurred during treatment. All patients had clinical improvement of their haemangiomas.
Conclusions This study suggests that initiating treatment during outpatient observation may be a reasonable alternative to inpatient admission. In addition, expensive testing may not be necessary during pre-treatment screening when the physical examination is normal.
(Received June 18 2011)
(Accepted October 26 2011)
(Online publication December 14 2011)
c1 Correspondence to: Dr J. L. Dyme, MD, Division of Pediatric Cardiology, Department of Pediatrics, Hackensack University Medical Center, 155 Polifly Road, Suite 106, Hackensack, NJ 07601, New Jersey, United States. Tel: +1 201 487 7617; Fax: +1 201 342 5341; E-mail: firstname.lastname@example.org